收藏切换
Observation on the high dose dexamethasone combined with recombinant human interleukin-11 in the treatment of the patients with newly diagnosed primary immune thrombocytopenia
收藏切换
Yu-li WANG, Yu-hong TANG, Yang SI, Yan-fang ZHANG, Qi ZHU*
World Clinical Drug | 2018, 39(1) : 19 - 23
Less
收藏切换
World Clinical Drug | 2018, 39(1): 19-23
• Article •
Observation on the high dose dexamethasone combined with recombinant human interleukin-11 in the treatment of the patients with newly diagnosed primary immune thrombocytopenia
Full
Yu-li WANG, Yu-hong TANG, Yang SI, Yan-fang ZHANG, Qi ZHU*
Affiliations
  • Department of Hematology, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 201900, China
Published: 2018-01-10 doi: 10.13683/j.wph.2018.01.005
Outline
收藏切换
Objective

To investigate clinical efficacy of the high dose dexamethasone (HD-DXM) combined with recombinant human interleukin-11 (rhIL-11) in the treatment of the adult patients with newly diagnosed primary immune thrombocytopenia (ITP).

Methods

The medical records of 47 newly diagnosed primary ITP patients with bleeding symptoms or risks, who received HD-DXM alone or in combination with rhIL-11, were retrospectively identified and systemically analyzed. These patients were divided into four groups according to their bleeding scale prior to initiation of treatment and therapeutic schedules, including monotherapy group (dexamethasone 40 mg/d on days 1-4) and combination therapy group [dexamethasone 40 mg/d on days 1-4 combined with rhIL-11 25 μg/(kg·d) on days 1-7] as well as high-risk group (bleeding scores≥5) and low-risk group (bleeding scores < 5). The clinical efficacy, onset time of response, duration of response, the platelet recovery level and treatment related toxicity profiles among different groups were systematically analyzed and compared.

Results

The platelet recovery level and duration of response in combination therapy group were more pronounced than those in monotherapy group [(97.38±49.18)×109/L vs (158.72±41.72)×109/L and (18.15±4.54) d vs (12.43±3.18) d, P < 0.01]. The rates of complete response (CR), response (R), no response (NR) and relapse as well as onset time of response showed no statistical difference between combination and monotherapy groups (P>0.05). Furthermore, the CR rate and platelet recovery level as well as duration of response in the ITP patients with high bleeding scores in combination therapy group was significantly higher than those in monotherapy group [37.50% vs 21.74%, (226.75±52.68)×109/L vs (166.72±39.28)×109/L and (18.45±4.48) d vs (11.84±3.73) d, P<0.01]. Meanwhile, the rates of R, NR and relapse as well as onset time of response in high bleeding scores patients were shown little difference between combination therapy and monotherapy group (P>0.05). The platelet recovery level as well as duration of response in ITP patients with low bleeding scores in combination group were significantly higher than those in monotherapy group [(184.36±44.50)×109/L vs (148.48±46.37)×109/L and (17.72±3.32) d vs (14.52±4.18) d, P<0.05]. In addition, the rates of CR, R, NR and relapse as well as onset time of response in ITP patients with low bleeding scores were shown little difference between combination and monotherapy group (P>0.05). Concerning treatment related toxicity profiles, no grade 3~4 toxicity occurred in patients of combination and monotherapy group.

Conclusion

HD-DXM combined with rhIL-11 is an effective and well tolerated therapeutic approach for the adult patients with newly diagnosed primary ITP. It can increase the platelet recovery level and improve response duration as well as clinical efficacies in the patients with high bleeding risk, which serves as a platform for the design of future prospective clinical trials.

immune thrombocytopenia  /  newly diagnosed  /  dexamethasone  /  recombinant human interleukin-11
王育丽, 唐宇宏, 司阳, 张彦芳, 朱琦. 大剂量地塞米松联合重组人白介素-11治疗新诊断原发免疫性血小板减少症的观察性研究. 世界临床药物, 2018 , 39 (1) : 19 -23 . DOI: 10.13683/j.wph.2018.01.005
Yu-li WANG, Yu-hong TANG, Yang SI, Yan-fang ZHANG, Qi ZHU. Observation on the high dose dexamethasone combined with recombinant human interleukin-11 in the treatment of the patients with newly diagnosed primary immune thrombocytopenia[J]. World Clinical Drug, 2018 , 39 (1) : 19 -23 . DOI: 10.13683/j.wph.2018.01.005
Year 2018 volume 39 Issue 1
15
4
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2018.01.005
  • Receive Date:2017-10-25
  • Online Date:2026-11-19
  • Published:2018-01-10
Article Data
Affiliations
History
  • Received:2017-10-25
  • Revised:2017-11-29
Funding
Affiliations
    Department of Hematology, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 201900, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2018.01.005
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT